Literature DB >> 36008747

HMOX1 silencing prevents doxorubicin-induced cardiomyocyte injury, mitochondrial dysfunction, and ferroptosis by downregulating CTGF.

Jia Qian1, Wenting Wan1, Min Fan2.   

Abstract

OBJECTIVES: Doxorubicin is a type of effective antitumor drug but can contribute to cardiomyocyte injuries. We aimed to dissect the mechanism of the HMOX1/CTGF axis in DOX-induced cardiomyocyte injury, mitochondrial dysfunction, and ferroptosis.
METHODS: Bioinformatics analysis was conducted to retrieve differentially expressed genes in a DOX-induced mouse model. Mouse cardiomyocytes, HL-1 cells, were induced with l µM DOX, after which gain- or loss-of-function assays were applied. CCK-8, fluorescent probe assay, flow cytometry, and corresponding kits were employed to detect cell viability, ROS levels, mitochondrial membrane potential and cell apoptosis, and GSH and Fe2+ contents, respectively. qRT-PCR or Western blot assay was adopted to test HMOX1, CTGF, BCL-2, Caspase3, Cleaved-Caspase3, and GPX4 expression.
RESULTS: Bioinformatics analysis showed that HMOX1 and CTGF were highly expressed in DOX-induced mice and correlated with each other. Also, HMOX1 and CTGF expression was high in HL-1 cells after DOX treatment, along with an obvious decrease in cell viability and GSH and GPX4 expression, an increase in ROS levels, apoptosis, and Fe2+ contents, and mitochondrial membrane potential dysfunction or loss. HMOX1 or CTGF silencing diminished cell apoptosis, Cleaved-Caspase3 expression, Fe2+ contents, and ROS levels, enhanced cell viability and the expression of GSH, GPX4, and BCL-2, and recovered mitochondrial membrane potential in DOX-induced HL-1 cells. Nevertheless, the effects of HMOX1 silencing on the viability, apoptosis, ferroptosis, and mitochondrial dysfunction of DOX-induced HL-1 cells were counteracted by CTGF overexpression.
CONCLUSIONS: In conclusion, HMOX1 silencing decreased CTGF expression to alleviate DOX-induced injury, mitochondrial dysfunction, and ferroptosis of mouse cardiomyocytes.
© 2022. The Author(s), under exclusive licence to The Japanese Association for Thoracic Surgery.

Entities:  

Keywords:  CTGF; Cardiotoxicity; Cell apoptosis; Doxorubicin; Ferroptosis; HMOX1; Mitochondrial dysfunction

Year:  2022        PMID: 36008747     DOI: 10.1007/s11748-022-01867-7

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  47 in total

Review 1.  Doxorubicin: nanotechnological overviews from bench to bedside.

Authors:  Maximiliano Cagel; Estefanía Grotz; Ezequiel Bernabeu; Marcela A Moretton; Diego A Chiappetta
Journal:  Drug Discov Today       Date:  2016-11-23       Impact factor: 7.851

Review 2.  Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways.

Authors:  Jie Wang A; Jingjing Zhang; Mengjie Xiao; Shudong Wang; Jie Wang B; Yuanfang Guo; Yufeng Tang; Junlian Gu
Journal:  Cell Mol Life Sci       Date:  2021-01-13       Impact factor: 9.261

3.  EGF Protects Cells Against Dox-Induced Growth Arrest Through Activating Cyclin D1 Expression.

Authors:  Chun-Xia Yao; Jia-Chen Shi; Cai-Xia Ma; Cheng-Juan Xiong; Yang-Liu Song; Shu-Feng Zhang; Shan-Feng Zhang; Ming-Xi Zang; Li-Xiang Xue
Journal:  J Cell Biochem       Date:  2015-08       Impact factor: 4.429

Review 4.  An overview of doxorubicin formulations in cancer therapy.

Authors:  Sangeeta Rivankar
Journal:  J Cancer Res Ther       Date:  2014 Oct-Dec       Impact factor: 1.805

Review 5.  Host heme oxygenase-1: Friend or foe in tackling pathogens?

Authors:  Nisha Singh; Zeeshan Ahmad; Navin Baid; Ashwani Kumar
Journal:  IUBMB Life       Date:  2018-05-14       Impact factor: 3.885

Review 6.  The sinister face of heme oxygenase-1 in brain aging and disease.

Authors:  Hyman M Schipper; Wei Song; Ayda Tavitian; Marisa Cressatti
Journal:  Prog Neurobiol       Date:  2018-07-29       Impact factor: 11.685

Review 7.  Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies.

Authors:  Nanthip Prathumsap; Krekwit Shinlapawittayatorn; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Eur J Pharmacol       Date:  2019-11-20       Impact factor: 4.432

Review 8.  Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance.

Authors:  Hamdan S Al-Malky; Sameer E Al Harthi; Abdel-Moneim M Osman
Journal:  J Oncol Pharm Pract       Date:  2019-10-09       Impact factor: 1.809

9.  Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway.

Authors:  Can Hu; Xin Zhang; Peng Song; Yu-Pei Yuan; Chun-Yan Kong; Hai-Ming Wu; Si-Chi Xu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Redox Biol       Date:  2020-10-07       Impact factor: 11.799

10.  Acyl-CoA thioesterase 1 prevents cardiomyocytes from Doxorubicin-induced ferroptosis via shaping the lipid composition.

Authors:  Yunchang Liu; Liping Zeng; Yong Yang; Chen Chen; Daowen Wang; Hong Wang
Journal:  Cell Death Dis       Date:  2020-09-15       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.